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Abstract 
Background: Germline mutations in PALB2 gene make a small contribution to heritable breast cancer susceptibility. 
A recent report has revealed that women with mutations in the PALB2 gene were more than nine times as likely to 
develop breast cancer compared to those without. The aim of this study is to understand the status of PALB2 muta-
tions among Chinese high-risk breast cancer patients in a multi-ethnic region in China.
Methods: 152 patients with hereditary predisposition to breast cancer from the Xinjing region of China were 
enrolled in the study, and 100 control samples from healthy women were collected in the same locality. We 
sequenced the coding sequences and flanking intronic regions of PALB2 gene from DNA samples obtained from all 
subjects by direct sequencing.
Results: A total of 4 deleterious PALB2 mutations were identified in 152 breast cancer patients with a prevalence of 
about 2.6 % (4/152). The PALB2 mutation prevalence was 3.2 % (3/95) in cases with family history of breast cancer. In 
addition to the four deleterious mutations, we identified nine missense variants in 12 patients, using the prediction 
Softwares SIFT and PolyPhen, four of which might be disease associated (in 5 patients). Two of the 4 patients with 
deleterious mutations and 2 of the 5 patients presenting putative deleterious missense mutations had triple-negative 
breast cancer. No PALB2 mutation carriers were identified in 100 healthy controls.
Conclusion: PALB2 mutations account for a small, but not negligible, proportion of patients with hereditary predis-
position to breast cancer in the Xinjing region of China.
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Background
Breast cancer is one of the most common cancers in 
women worldwide [1]. However, the exact mechanisms 
of breast cancer are still poorly understood. Previous 
studies showed that breast cancer has an inherited com-
ponent [2], and the high-penetrance breast cancer pre-
disposing genes, BRCA1 and BRCA2, account for up to 
10–40 % of inherited breast cancer [3, 4]. Other relevant 
genes also contribute to inherited breast cancer, among 
these genes is PALB2 (Partner and Localizer of BRCA2) 
gene. PALB2 is located on chromosome 16p12.2 span-
ning approximately 38  kb, containing 13 exons and 12 
introns, and encodes for a protein involved in BRCA2-
related pathways [5]. PALB2 indirectly affects the expres-
sion of BRCA2, and the loss-of-function mutations in 
BRCA2 usually cause genetic instability, avoiding the 
defense system, resulting in non-controlling cell prolifer-
ation and thereby inevitably leading to tumorigenesis [6, 
7]. It has been discovered that heterozygosity for loss-of-
function mutations at PALB2 increases risk of developing 
breast cancer two- to ninefold [8, 9].
Inherited PALB2 mutations associated with increased 
risks of developing breast cancer have been identified in 
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families from many parts of the world, including China. 
To date, only a few studies have been reported on PALB2-
associated breast cancer in China, and the revaluated 
studies only involved ethnic Han Chinese [10, 11]. China 
is a multiple ethnic country comprising 56 ethnic groups. 
Xinjiang is the largest administrative region located in 
the northwest of China. It is home to a number of dif-
ferent ethnic groups including the Han, Uyghur, Kazakh, 
Hui, Kyrgyz, Mongol, etc. But thus far, inherited PALB2 
mutations has not been screened in Xinjiang population. 
For this purpose, we sequenced the complete coding and 
flanking regulatory regions of PALB2 from constitutional 
DNA of 152 patients with hereditary predisposition to 
breast cancer, all previously employed to study the distri-
bution of germline mutations in BRCA1, BRCA2 [12, 13]. 
Here, we present the identification of PALB2 mutations 




All patient cases were recruited from Xinjiang, China. 
They had a definite pathological diagnosis of breast 
cancer and received the standard treatment in our hos-
pital during the period 2005–2014. Participants were 
patients with breast cancer who had family history, early 
onset, male breast cancer, or bilateral breast cancer (BI-
BC). A total of 152 patients were eligible for testing. 
Among them, 33 were early onset cases diagnosed below 
35  years of age, 95 cases had family history of breast 
cancer, 24 had bilateral breast cancer, 4 had male breast 
cancer, and 48 had triple-negative breast cancer. In the 
included patients, the ethnic composition were 104 Han, 
28 Uyghur, 8 Hui, 7 Kazakh, 3 Mongol, and 2 Xibo. The 
mean age at diagnosis was 40.6 years (range 24–73 years). 
DNAs from 100 control samples from healthy women 
were collected in the same locality. The control group 
from the health women of the outpatient clinic had no 
family history of cancer. Their blood was collected and 
they agreed to give blood. The age of the individuals was 
range 20–62 years.
The study was approved by the Ethics Committee (IRB 
approval number: XJYD1320) of the Cancer Hospital of 
Xinjiang Medical University, and informed consent was 
obtained from each participant.
Genomic DNA sequencing
Genomic DNA was isolated from 5  ml of peripheral 
blood and stored in 10  mM Tris (pH8) EDTA at 4  °C. 
PALB2 exons, flanking intronic regions (50–100  bp 
in length), and 5′-and 3′-untranslated regions (UTR) 
were evaluated from all subjects. We adopted the direct 
sequencing method. DNAs were amplified using Plati-
num Taq DNA polymerase (Invitrogen). Sequence 
reactions were used on the Illumina HiSeq and MiSeq 
platforms. Sequences were analyzed using ANNOVAR 
software.
Prediction of pathogenicity of missense variants
Potential consequences of missense mutations were 
obtained using the prediction Softwares SIFT (http://




PALB2 deleterious mutations were identified in 4 patients 
(Table  1) including a novel frameshift mutation in exon 
4(c.1039_1040insA,p.E347fs) and exon 12(c.3294_3298
delTCGTC,p.1098_1100del) in addition to a frameshift 
mutation in exon 4(c.509-510delGA,p. R170fs) and a 
truncating mutation in exon 5(c.2386G>T,p.G796X) that 
have been previously reported [14] in HGMD (Human 
Gene Mutation Database). The prevalence of the PALB2 
germline mutation was about 2.6  % (4/152). No PALB2 
mutation carriers were identified in 100 healthy controls. 
In the 152 patients, 95 cases had family history of breast 
cancer, three patients were identified deleterious muta-
tions, the PALB2 mutation prevalence was 3.2 % (3/95).
PALB2 missense variants and prediction of pathogenicity
In addition to the four deleterious mutations, we identi-
fied nine missense variants in 12 patients (Table 2) includ-
ing 8 novel missense variants in exon 4(c.1273G>A,p.
V425M; c.925A>G, p.I309V; c.691A>G,p.K231E), exon 
10(c.3035C>T,p.T1012I), exon 12(c.3306C>G,p.S1102R), 
exon 7(c.2720A>G,p.E907G; c.2699C>T,p.A900V) and 
Table 1 Inherited truncating mutations in PALB2
Genomic locale Exon Nucleotide change Protein change Type
chrl6:23,619,237-41 12 c.3294_3298delTCGTC p.1098_1100del Frameshift
chrl6:23,646,828 4 c.1039_1040insA p.E347fs Frameshift
chrl6:23,647,357-58 4 c.509-510delGA p. R170fs Frameshift
chrl6:23,641,089 5 c.2386 G>T p.G796X Nonsense
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exon 2(c.64G>A,p.A22T). The missense variants in exon 
4(c.925A>G,p.I309V) was also identified in one patient 
of 100 healthy controls. To determine whether the mis-
sense variants were pathogenic, we further analyzed 
them using the prediction Softwares SIFT and PolyPhen. 
The application of the two different prediction programs 
and conservation profiles indicated that only four of 
them might be disease associated (c.3035C>T,p.T1012I; 
c.3054G>C,p.E1018D; c.2720A>G,p.E907G; c.64G>A,p.
A22T).
Patients’ characteristics of PALB2 truncating and putative 
deleterious missense mutations
In total, we identified four deleterious mutations and four 
putative pathogenic missense mutations in the 152 cases. 
The family history and histopathology of the tumor tis-
sues of the patients are indicated in Table 3. Among the 
four patients with deleterious mutations, 3 had family 
history of breast cancer and 1 had bilateral breast can-
cer, and 2 had triple-negative breast cancer (estrogen and 
progesterone receptor negative, and HER2/neu nega-
tive). Of the five patients with putative deleterious mis-
sense mutations, 4 had positive family history and 1 was 
an early-onset breast cancer. The patient with the PALB2 
mutation, c.64G>A, was diagnosed with bilateral breast 
cancer and had positive family history.
In the included patients, 48 had triple-negative breast 
cancer, the PALB2 mutation prevalence was 4.2 % (2/48). 
Among the triple-negative breast cancers, 22 were 
selected cases with a family history or bilateral breast 
cancers, the PALB2 mutation prevalence was 9.1  % 
(2/22), for 2 of four patients with deleterious mutations 
had triple-negative breast cancer, and had family history 
or bilateral breast cancer.
Discussion
In a recent report in the new England Journal of Medi-
cine [9], women with inherited loss-of-function muta-
tions in the PALB2 gene were found to be more than nine 
times as likely to develop breast cancer, compared to the 
general population. PALB2 was identified via a search 
for novel components of endogenous BRCA2-containing 
complexes and is critical for its localization to chroma-
tin and recruitment to double-strand breaks [15]. PALB2 
is also recruited by BRCA1 in response to DNA damage 
and serves as a linker between BRCA1 and BRCA2 nec-
essary for BRCA2-mediated HR repair [16]. The PALB2 
germline mutations and their carrier frequencies are 
Table 2 PALB2 missense variants and prediction of pathogenicity
Exon Nucleotide change Protein change Mutation cases SIFT score Polyphen score
10 c.3035C>T p.T1012I 1 0 0.997
7 c.2720A>G p.E907G 1 0.02 0.983
4 c.1273G>A p.V425M 1 0.01 0.002
4 c.925A>G p.I309V 3 1 0
4 c.691A>G p.K231E 1 0.04 0.023
10 c.3054G>C p.E1018D 2 0.03 0.95
12 c.3306C>G p.S1102R 1 0.01 0.119
7 c.2699C>T p.A900V 1 0.02 0.024
2 c.64G>A p.A22T 1 0 0.98
Table 3 Patient’s characteristics of PALB2 truncating and putative deleterious missense mutations
BC breast cancer, BI-BC bilateral breast cancer, HR hormone receptor, HER-2 human epidermal growth factor receptor 2
Nucleotide change Type Ethnic group Age at diagnosis HR HER-2 Inclusion reason
c.3294_3298delTCGTC Frameshift Han 65 1 1 2 daughters BC
c.509-510delGA Frameshift han 44 1 0 Mother and sister BC
c.1039_1040insA Frameshift Han 46 0 0 Bilateral BC
c.2386 G>T Nonsense Uyghur 33 0 0 mother BC
c.3035C>T Missense Han 45 1 0 sister BC
c.2720A>G Missense Kazakh 41 0 0 sister BC
c.3054G>C Missense Han 50 0 1 aunt BC
Han 34 1 0 Early onset
c.64G>A Missense Han 50 0 0 BI-BC and mother BC
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0.1–3.6  % among different populations [10, 14, 17–20], 
including China. Germline mutations in PALB2 gene 
make a small contribution to the heritable breast cancer 
susceptibility and increased risk for breast cancer.
The prevalence of PALB2 mutations varies due to 
founder mutation effects and other environmental and 
geographical factors. To date, only a very limited num-
ber of studies have focused on the association between 
PALB2 mutations and hereditary predisposition to breast 
cancer in China, and ethnic Han Chinese patients were 
enrolled in most of these studies, with no study address-
ing multiple ethnic groups in China. In our study, 152 
specimen of patients with hereditary predisposition 
to breast cancer (including patients with early-onset 
breast cancer, family history of breast or ovarian can-
cer, bilateral cancer, or male breast cancer) were studied 
for PALB2 mutations. Four (2.6  %) of the patients were 
identified to harbor a deleterious PALB2 mutation. The 
result are consistent with the previous reports [10, 14, 
17–20]. In the included 152 patients, the ethnic composi-
tion were 104 Han, 28 Uyghur, 8 Hui, 7 Kazakh, 3 Mon-
gol, and 2 Xibo. Among the four patients with deleterious 
mutations, 3 were Han, 1 was Uyghur, so variation of the 
PALB2 mutations among different ethnic groups could 
not be obtained, for the number of participants in some 
of the groups was not sufficient for statistical analysis and 
comparison.
Of the 4 PALB2 deleterious mutations identified in our 
study, 2 have been previously reported and 2 were novel 
(Table  1). An interesting mutation of c.509–510delGA 
carried by ethnic Han Chinese patient was first described 
(with the highest frequency so far) in the Polish popula-
tion [21]. Other studies reporting this mutation were all 
carried by European ancestry on their familial lineages 
with histories of breast cancer, suggesting that this muta-
tion may have a European origin. PALB2 c.2386G>T has 
also been reported in families from Europe [22], with 
much lower frequency or in single patients. The muta-
tion was carried by ethnic Uyghur Chinese patient in 
our study. PALB2 c.509-510delGA and c.2386G>T has 
been first reported in Asia; Is it a founder mutation? The 
spectrum of PALB2 mutations in the Chinese popula-
tion may be larger if larger groups are analyzed. In this 
study, we identified nine missense variants in 12 patients 
(Table 2). Using the prediction Softwares SIFT and Poly-
Phen, four of the missense variants (c.3035C>T,p.T1012I; 
c.3054G>C,p.E1018D; c.2720A>G,p.E907G; c.64G>A,p.
A22T) indicated putative pathogenic mutation. Similar 
to the mutation spectrum observed in BRCA1/2, protein 
truncating mutations in PALB2 are associated with breast 
cancer. There is no evidence that missense mutations in 
PALB2 play a significant role in breast cancer predisposi-
tion [23, 24]. Further research is needed to clarify effects 
of these putative pathogenic missense mutations on pro-
tein function.
Male breast cancer is significantly associated with 
BRCA2 mutations [25]. Our previous study has shown 
that male breast cancer mutations were BRCA2 mutations.
A small number of the pedigrees reported in the lit-
erature to carry protein truncating PALB2 mutations 
included cases of male breast cancer [26]. In our study, 
the four cases of male breast cancer had no detect-
able PALB2 mutations. Truncating PALB2 heterozygous 
mutations have been identified in bilateral breast cancer 
patients [18]. In this study, one of the four patients with 
deleterious mutations was bilateral breast cancer. So we 
think that PALB2 mutations contribute to a small fraction 
of bilateral breast cancer in the Xinjiang region of China. 
Some information about the general morphology of 
breast tumors with PALB2 mutation is available. Carriers 
with a family history of breast cancer were more likely to 
have triple-negative breast cancer [27]. In our study, two 
of the four patients with deleterious mutations had also 
triple-negative breast cancer, and two of the five puta-
tive deleterious missense mutations were triple-negative 
breast cancers. As previously observed [13], triple-neg-
ative breast cancers tend to harbor BRCA1/2 mutation 
which appears to be slightly overrepresented in PALB2-
related breast cancers. Therefore, PALB2 mutation might 
be associated with triple-negative breast cancer.
Conclusion
The results show that mutations in PALB2 are rare, but 
along with BRCA1 and BRCA2 are key breast cancer sus-
ceptibility genes in the Xinjiang region of China. PALB2 
mutation may be associated with triple-negative breast 
cancer, the same as immunohistochemical features of 
BRCA1/2 mutation-associated breast tumors.
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